Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update

BEDFORD, Mass--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter ended September 30, 2022, and provided updates on its ophthalmology pipeline. “We presented arguably the most important clinical data in the Company’s history at this year’s AAO meeting” commented Antony Mattessich, Preside